Novo Nordisk has nominated board members for re-election as part of its restructuring efforts. Three new members could join the board, which after a restructuring in October 2025 consists mostly of recently appointed members[1][2]. The company plans to cut 9,000 jobs globally, or about 11% of its workforce, including dozens of employees at its largest manufacturing facility in Clayton, North Carolina, where the drugs Wegovy and Ozempic are made[1][2][6]. The restructuring is new CEO Mike Doustdar's first major move and is expected to deliver annual savings of around DKK 8 billion (approximately US$1.25 billion) by 2026[2][3]. The firm is facing pressure from competition from Eli Lilly and cheaper copycats, leading to a cut in operating profit growth forecast for 2025 and an expected decline in sales of 5-13% in 2026[2][4]. In 2025, sales will grow by 6.4% to DKK 309.06 billion and the board will propose a dividend of DKK 11.70 per share[4]. These changes also respond to demands from the Donald Trump administration to increase production in the US, despite a $4.1 billion investment to expand the Clayton plant[1][6].